A Meta-Analysis Study of SOD1-Mutant Mouse Models of ALS to Analyse the Determinants of Disease Onset and Progression

被引:6
|
作者
Ciuro, Maria [1 ]
Sangiorgio, Maria [1 ]
Leanza, Giampiero [2 ,3 ]
Gulino, Rosario [1 ,3 ]
机构
[1] Univ Catania, Dept Biomed & Biotechnol Sci, Physiol Sect, I-95123 Catania, Italy
[2] Univ Catania, Dept Drug & Hlth Sci, I-95125 Catania, Italy
[3] Univ Catania, Mol Preclin & Translat Imaging Res Ctr IMPRonTE, I-95125 Catania, Italy
关键词
ALS epidemiology; ALS pathogenesis; amyotrophic lateral sclerosis; mathematical model; meta-analysis; mouse; superoxide dismutase 1; symptom onset; AMYOTROPHIC-LATERAL-SCLEROSIS; PRION-LIKE PROPAGATION; SPINAL-CORD; MICE; VARIABILITY; PLASTICITY; MECHANISMS; PHENOTYPE; TDP-43;
D O I
10.3390/ijms24010216
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A complex interaction between genetic and external factors determines the development of amyotrophic lateral sclerosis (ALS). Epidemiological studies on large patient cohorts have suggested that ALS is a multi-step disease, as symptom onset occurs only after exposure to a sequence of risk factors. Although the exact nature of these determinants remains to be clarified, it seems clear that: (i) genetic mutations may be responsible for one or more of these steps; (ii) other risk factors are probably linked to environment and/or to lifestyle, and (iii) compensatory plastic changes taking place during the ALS etiopathogenesis probably affect the timing of onset and progression of disease. Current knowledge on ALS mechanisms and therapeutic targets, derives mainly from studies involving superoxide dismutase 1 (SOD1) transgenic mice; therefore, it would be fundamental to verify whether a multi-step disease concept can also be applied to these animal models. With this aim, a meta-analysis study has been performed using a collection of primary studies (n = 137), selected according to the following criteria: (1) the studies should employ SOD1 transgenic mice; (2) the studies should entail the presence of a disease-modifying experimental manipulation; (3) the studies should make use of Kaplan-Meier plots showing the distribution of symptom onset and lifespan. Then, using a subset of this study collection (n = 94), the effects of treatments on key molecular mechanisms, as well as on the onset and progression of disease have been analysed in a large population of mice. The results are consistent with a multi-step etiopathogenesis of disease in ALS mice (including two to six steps, depending on the particular SOD1 mutation), closely resembling that observed in patient cohorts, and revealed an interesting relationship between molecular mechanisms and disease manifestation. Thus, SOD1 mouse models may be considered of high predictive value to understand the determinants of disease onset and progression, as well as to identify targets for therapeutic interventions.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Relationship between neuropathology and disease progression in the SOD1G93A ALS mouse
    Yang, Wendy W.
    Sidman, Richard L.
    Taksir, Tatyana V.
    Treleaven, Christopher M.
    Fidler, Jonathan A.
    Cheng, Seng H.
    Dodge, James C.
    Shihabuddin, Lamya S.
    EXPERIMENTAL NEUROLOGY, 2011, 227 (02) : 287 - 295
  • [22] MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models
    Muller, Florian L.
    Liu, Yuhong
    Jernigan, Amanda
    Borchelt, David
    Richardson, Arlan
    van Remmen, Holly
    MUSCLE & NERVE, 2008, 38 (03) : 1173 - 1183
  • [23] Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS
    Foust, Kevin D.
    Salazar, Desiree L.
    Likhite, Shibi
    Ferraiuolos, Laura
    Ditsworth, Dara
    Ilieva, Hristelina
    Meyer, Kathrin
    Schmelzer, Leah
    Braun, Lyndsey
    Cleveland, Don W.
    Kaspar, Brian K.
    MOLECULAR THERAPY, 2013, 21 (12) : 2148 - 2159
  • [24] Therapeutically increasing mutant SOD1 metallation status attenuates disease symptoms in an ALS mouse model
    Lim, N.
    Roberts, B. R.
    Donnelly, P. S.
    Lim, S.
    Beckman, J. S.
    Barnham, K. J.
    Li, Q.
    White, A. R.
    Crouch, P. J.
    JOURNAL OF NEUROCHEMISTRY, 2012, 123 : 16 - 16
  • [25] A bird's eye view of the SOD1 mouse: Using meta-analysis to guide clinical trials in familial ALS
    Benatar, Michael
    NEUROLOGY, 2007, 68 (12) : A404 - A404
  • [26] Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS
    Koh, Seong-Ho
    Kim, Youngchul
    Kim, Hyun Y.
    Hwang, Sejin
    Lee, Chang Ho
    Kim, Seung H.
    EXPERIMENTAL NEUROLOGY, 2007, 205 (02) : 336 - 346
  • [27] Metabolic and Stress Response Changes Precede Disease Onset in the Spinal Cord of Mutant SOD1 ALS Mice
    Pharaoh, Gavin
    Sataranatarajan, Kavithalakshmi
    Street, Kaitlyn
    Hill, Shauna
    Gregston, Jake
    Ahn, Bumsoo
    Kinter, Caroline
    Kinter, Michael
    Van Remmen, Holly
    FRONTIERS IN NEUROSCIENCE, 2019, 13
  • [28] Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice
    Lobsiger, Christian S.
    Boillee, Severine
    McAlonis-Downes, Melissa
    Khan, Amir M.
    Feltri, M. Laura
    Yamanaka, Koji
    Cleveland, Don W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (11) : 4465 - 4470
  • [29] Unveiling the SOD1-mediated ALS phenotype: insights from a comprehensive meta-analysis
    Domi, Teuta
    Schito, Paride
    Sferruzza, Giacomo
    Russo, Tommaso
    Pozzi, Laura
    Agosta, Federica
    Carrera, Paola
    Riva, Nilo
    Filippi, Massimo
    Quattrini, Angelo
    Falzone, Yuri Matteo
    JOURNAL OF NEUROLOGY, 2024, 271 (03) : 1342 - 1354
  • [30] Unveiling the SOD1-mediated ALS phenotype: insights from a comprehensive meta-analysis
    Teuta Domi
    Paride Schito
    Giacomo Sferruzza
    Tommaso Russo
    Laura Pozzi
    Federica Agosta
    Paola Carrera
    Nilo Riva
    Massimo Filippi
    Angelo Quattrini
    Yuri Matteo Falzone
    Journal of Neurology, 2024, 271 : 1342 - 1354